JND003 is a selective ERRα agonist alleviating nonalcoholic fatty liver disease and insulin resistance. Pharmacokinetics and tissue distribution assays were performed at Medicilon

Over 20 years of experience in R&D

Learn more

01 Drug Discovery

Chemistry Research

Biology Research

Early Pharmacokinetics

02 Pharmaceutical Research

Intermediates

Active Pharmaceutical Ingredients

Pharmaceutical preparation

Analytical Method Development and Quality Control

CMC Filings

Analytical Testing Center

03 Preclinical Research

Pharmacology & Pharmacodynamics

Drug Safety Evaluation

DMPK

Bioanalysis

IND Filings

01 One-stop Integrated Services

Liposome Drug Development Service Platform

Drug Discovery Platform

Pharmaceutical Research Platform

Preclinical Research Services

Botanical Drug Preclinical R&D Technology Platform

02 Innovative Drug Services

ADC R&D Service Platform

PROTAC R&D Service Platform

mRNA Vaccine Bioanalysis Platform

Non-clinical Research for Cellular Immunotherapies

Nucleic Acid Drug R&D Platform

Peptide Drug Conjugate (PDC) R&D Service Platform

Antibody R&D Service

03 Key Technical Services for Drug R&D

Cytokine and Biomarker Detection Platform

Metabolite Identification (MetID) Service Platform

Drug Forming Research Platform

Flow Cytometry Technology Platform

SEND Format Conversion Platform

Flow Sorting Platform

NanoString nCounter Detection Platform

Routes of Drug Administration Platform

04 Drug Efficacy Evaluation for Common Diseases

IO Pharmacodynamic Model Evaluation Platform

Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases

Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

05 Advanced Preparation R&D

Inhalation drug R&D platform

Ophthalmic drug R&D platform

Skin Topical Preparation R&D Platform

06 Targeted Drugs R&D Services

STAT3-targeted Drugs R&D Service

GLP-1 New Drug R&D Service

KRAS-targeted Drugs R&D Service

2024-07-22Medicilon Events

The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together

On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.

Learn more

2024-07-22Medicilon Events

5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"

Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.

Medicilon 688202

RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER

Intellectual Property Protection

U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Shanghai Public Network Security File No. 31011502018888 | Website Map

JND003 is a selective ERRα agonist alleviating nonalcoholic fatty liver disease and insulin resistance. Pharmacokinetics and tissue distribution assays were performed at Medicilon

2023-07-11

Page View：

3(1).jpg

Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver diseases. Estrogen-related receptor alpha (ERRα) is a viable target for NAFLD. JND003 is a potent and selective ERRα agonist alleviating nonalcoholic fatty liver disease and insulin resistance. JND003 is orally bioavailable and exhibits high grade of distribution in liver and abdominal adipose tissues. Pharmacokinetics (PK) and Tissue Distribution Assays of JND003 were performed at Medicilon.

Reference:

Liufeng Mao, et al. Discovery of JND003 as a New Selective Estrogen-Related Receptor α Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance. ACS Bio Med Chem Au. 2022 Jun 15;2(3):282-296. doi: 10.1021/acsbiomedchemau.1c00050.